Amyloidosis trials in France

In France 32 Also abroad 184

32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis
Where
Caen, Lille
Age
18 years to 100 years
People
35
Run by
University Hospital, Caen
See details and how to joinNCT04535349
Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Creteil, Marseille, Paris Cedex 18, Rennes, Toulouse Cedex 9
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
No phaseTaking people
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Where
Toulouse
Age
18 years and over
People
2,200 worldwide
Run by
Idoven 1903 S.L.
See details and how to joinNCT06978660
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Nantes, Pierre-Bénite, Rennes, Toulouse
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
No phaseTaking people
Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients
Where
Marseille
Age
18 years and over
People
120
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06845644
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Créteil, Marseille, Paris, Rennes, Toulouse
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Amiens, Bron, Chambray-lès-Tours, Créteil, Dijon, La Roche-sur-Yon, La Tronche, Marseille, Metz-Tessy, Montpellier, Nantes, Nice, Paris, Pessac, Poitiers, Rennes, Toulon, Toulouse, Villeurbanne
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Chambray Les Tours, Creteil Cedex, Dijon, Fort De France Cedex, Grenoble Cedex 9, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 18, Pessac, Reims Cedex, Rennes Cedex 9, Rouen Cedex, Saint-Herblain, Strasbourg Cedex, Toulouse Cedex 9
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Where
Bordeaux, Bron, Créteil, Le Kremlin-Bicêtre, Marseille
People
1,500 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT04561518
No phaseTaking people
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Where
Nantes
People
10 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT05040373
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Creteil Cedex, Le Kremlin Bicetre Cedex, Marseille
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis
Where
Montpellier
Age
18 years and over
People
40
Run by
University Hospital, Montpellier
See details and how to joinNCT07494942
No phaseTaking people
Prevalence of Cardiac Thrombi in Cardiac Amyloidosis
Where
Dijon
Age
18 years and over
People
200
Run by
Centre Hospitalier Universitaire Dijon
See details and how to joinNCT07648303
No phaseTaking people
Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy
Where
Many Locations
Age
18 years and over
People
500
Run by
Bayer
See details and how to joinNCT07791160
Phase 2Taking people
Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis
Where
Nantes Cedex 1
Age
18 years and over
People
40
Run by
Nantes University Hospital
See details and how to joinNCT07549841 · EU 2025-523616-36-00
Phase 3Not yet taking people in France
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Bron, Chambray-lès-Tours, Créteil, Marseille, Montpellier, Paris, Pessac, Poitiers, Rennes, Saint-Herblain, Toulouse
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
No phaseTaking people
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy
Where
Lille
Age
18 years and over
People
30
Run by
GCS Ramsay Santé pour l'Enseignement et la Recherche
See details and how to joinNCT04849754
Phase 3Not yet taking people in France
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Where
Bordeaux, Créteil, Fort De France Cedex, Le Kremlin Bicetre Cedex, Rennes, Toulouse Cedex 9
Age
18 years and over
People
250 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Bordeaux, Créteil, Fort De France Cedex, Le Kremlin Bicetre Cedex, Rennes, Toulouse Cedex 9
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 2/3Enrolling by invitation
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Where
Le Kremlin-Bicetre
Age
18 years and over
People
72 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT05697861 · EU 2023-507385-11-00
No phaseNot yet taking people in France
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
Where
Pierre-Bénite
Age
18 years and over
People
100
Run by
Hospices Civils de Lyon
See details and how to joinNCT07721350
No phaseTaking people
Evaluation of Skin Tests in Biotherapy Allergies
Where
Angers
Age
18 years and over
People
70
Run by
University Hospital, Angers
See details and how to joinNCT06971848
No phaseTaking people
Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy
Where
Montpellier
Age
18 years and over
People
500
Run by
Clinique Saint Jean, France
See details and how to joinNCT07644325
No phaseTaking people
Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis
Where
Toulouse
Age
18 years to 99 years
People
100
Run by
University Hospital, Toulouse
See details and how to joinNCT04636684
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Where
Limoges Cedex 1, Toulouse Cedex 9
Age
18 years and over
People
76 worldwide
Run by
AbbVie
See details and how to joinNCT06158854 · EU 2023-503429-20-00